|Full Name||methyl-CpG binding domain protein 1|
|Product Description||Rabbit Polyclonal antibody to MBD1 (methyl-CpG binding domain protein 1)|
|Background||DNA methylation is the major modification of eukaryotic genomes and plays an essential role in mammalian development. Human proteins MECP2, MBD1, MBD2, MBD3, and MBD4 comprise a family of nuclear proteins related by the presence in each of a methyl-CpG binding domain (MBD). Each of these proteins, with the exception of MBD3, is capable of binding specifically to methylated DNA. MECP2, MBD1 and MBD2 can also repress transcription from methylated gene promoters. Five transcript variants of the MBD1 are generated by alternative splicing resulting in protein isoforms that contain one MBD domain, two to three cysteine-rich (CXXC) domains, and some differences in the COOH terminus. All five transcript variants repress transcription from methylated promoters; in addition, variants with three CXXC domains also repress unmethylated promoter activity. MBD1 and MBD2 map very close to each other on chromosome 18q21. [provided by RefSeq]|
|Synonyms||CXXC3 antibody, PCM1 antibody, RFT antibody, MBD1 antibody, the regulator of fibroblast growth factor 2 (FGF-2) transcription antibody, CXXC-type zinc finger protein 3 antibody, methyl-CpG-binding domain protein 1 antibody, methyl-CpG binding domain protein 1 isoform PCM1 antibody, protein containing methyl-CpG-binding domain 1 antibody, methyl-CpG binding domain protein 1 antibody|
|Cellular Localization||Nucleus speckle|
|Immunogen||Recombinant protein encompassing a sequence within the center region of human MBD1. The exact sequence is proprietary.|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Predict Reactivity Note||Bovine (80%)|